所谓的"猫三联"，并不是三种疫苗一起打，而是一针疫苗同时预防三种对猫咪危害最大的核心传染病。 而作为全球广泛应用的猫三联疫苗，妙三多的防护目标正是这三种最常见、最危险、最易传染的病毒： 猫瘟、猫鼻支和猫杯状病毒。 猫瘟发病急、死亡率高，幼猫感染后往往凶多吉少。而猫鼻支一旦感染，猫咪可能终身携带病毒，在应 激时反复发作，出现打喷嚏、流眼泪等症状。猫杯状则会导致口腔溃疡、肺炎，严重时同样危及生命。 这三种病毒传染性极强，可以通过人的衣物、鞋底、甚至空气传播——即便你的猫咪足不出户，风险依 然存在。 当你第一次把那只毛茸茸的小生命抱回家，心中涌起的喜悦与忐忑交织——从这一刻起，它的健康就交 到了你的手上。然而，面对宠物医生口中的"猫三联"，不少新晋铲屎官难免一脸茫然：猫三联是什么？ 为什么要打？到底预防哪些病？ 今天，我们就来揭开这个养猫入门的第一课。 当然，新手铲屎官难免会有疑虑：妙三多安全吗？效果可靠吗？事实上，妙三多作为进入中国多年的经 典猫三联疫苗，其安全性与有效性已经过全球市场和长时间的广泛验证。无数宠物医生之所以共同推荐 它，正是因为他们在临床实践中亲眼见证了多少猫咪因为及时接种而躲过一劫，也目睹了多少 ...

Core Insights - New Ruipeng Pet Hospital Group is shifting its strategy away from low-quality expansion, as emphasized by co-chairman Li Liang during the mid-year meeting in August 2025, following the departure of founder Peng Yonghe, which has sparked widespread discussion in the industry [1][3] - The operational control of New Ruipeng has been transferred to a representative of Hillhouse Capital, while Peng Yonghe has moved on to focus on AI medical technology and supply chain in a new venture [1][3] Company Overview - Founded in 1998 by veterinarian Peng Yonghe, Ruipeng Pet Hospital became the first listed pet medical company in China in 2016 [3] - In 2018, Ruipeng delisted from the New Third Board and formed New Ruipeng Group with significant investment from Hillhouse Capital, each holding approximately 40% of the company [3] - Despite becoming the largest pet medical platform in China, rapid expansion has led to significant financial losses, with revenues increasing from 4.784 billion to 5.74 billion yuan from 2021 to 2022, while net losses rose to 1.311 billion and 1.417 billion yuan respectively [3][4] Operational Challenges - The rapid expansion has resulted in management and service quality issues, leading to a talent gap in medical staff and dissatisfaction among employees due to high workloads and low compensation [3][4] - Consumer experience has been negatively impacted, with a reported 1,480 complaints on the Black Cat Complaint platform, focusing on issues like opaque pricing and over-treatment [4][8] Financial Performance - New Ruipeng's operational costs have surged, with labor costs rising from 22% of total revenue in 2015 to 52% in 2022, further squeezing profit margins [7] - The company has retracted its IPO application in the U.S. and is undergoing strategic contraction, reducing its number of stores from around 1,900 to approximately 1,600 [7][8] Industry Context - The challenges faced by New Ruipeng reflect broader issues within the Chinese pet medical industry, which has seen a saturation of stores and increasing operational costs, leading to a disconnect between consumer perceptions of high costs and companies' struggles with profitability [8][9] - Recent performance reports from other listed pet companies indicate similar trends, with revenue growth accompanied by declining net profits due to rising marketing expenses [9] Strategic Initiatives - New Ruipeng is focusing on specialization and digital transformation, establishing 15 specialized pet medical departments to enhance service quality [10] - The company is also exploring a network layout of "1+P+C" (one central hospital, specialized hospitals, and community clinics) to optimize resource allocation [10] - Peng Yonghe has invested 14 million yuan in Xiaowen Medical, which focuses on AI applications in the pet medical field, indicating a potential new growth area for the industry [10]